VIP antagonists enhance excitatory cholinergic neurotransmission in the human airway

H. Aizawa, H. Inoue, M. Shigyo, S. Takata, H. Koto, K. Matsumoto, N. Hara

研究成果: ジャーナルへの寄稿学術誌査読

5 被引用数 (Scopus)

抄録

It has been reported that a low concentration of exogenously applied vasoactive intestinal peptide (VIP) suppresses the release of acetylcholine (ACh) from vagus nerve terminals in the ferret and feline trachea. There has been, however, no documentation of the prejunctional action of VIP in the human airway. We observed the effects of VIP and VIP antagonists on cholinergic excitatory neuro-effector transmission in the human bronchus to study the possible role of endogenous VIP on excitatory neurotransmission. In the human bronchus, VIP (10-10 to 10-7 M) showed no effect on either the contractions evoked by electrical field stimulation (EPS) or those evoked by ACh. To investigate the possible role of endogenous VIP on the human bronchus, we observed the effects of the VIP antagonists [4-Cl-D-Phe6,Leu17]-VIP and [Ac-Tyr1,D-Phe2-]-GRF(1-29)-NH2 on excitatory neuroeffector transmission. Both VIP antagonists (10-8 M) significantly enhances the contractions evoked by EFS without affecting the ACh sensitivity of smooth muscle cells. These results indicate that VIP antagonists have a prejunctional action that enhances excitatory neurotransmission. This study suggests that endogenous VIP may suppresses ACh release from the vagus nerve terminals in the human airway. It is also suggested that exogenously applied VIP may be inactivated by some mechanism in the human airway.

本文言語英語
ページ(範囲)159-167
ページ数9
ジャーナルLung
172
3
DOI
出版ステータス出版済み - 5月 1994
外部発表はい

!!!All Science Journal Classification (ASJC) codes

  • 呼吸器内科

フィンガープリント

「VIP antagonists enhance excitatory cholinergic neurotransmission in the human airway」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル